This story has been updated from a previous version, which inadvertently omitted Aeris Capital as an investor.

NEW YORK (GenomeWeb News) – Tethys Bioscience has closed $25 million in Series D financing, which it plans to use to expand commercialization of its PreDx Diabetes Risk Score test.

The funding round was led by Aeris Capital, and included current investors MDV-Mohr Davidow Ventures, Kleiner Perkins Caulfield and Byers, and Intel Capital; and one new investor, Wasatch Advisors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.